![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-naïve Patients: Week 48 Results in Subgroups
Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging
|
|
|
Reported by Jules Levin
IDWeek 2018, October 3-7, 2018, San Francisco  
Christoph D. Spinner,1 Bruce Rashbaum,2,* Cheryl McDonald,3 Cristina Mussini,4 Donghan Luo,5 John Jezorwski,6 Kimberley Brown,5 Eric Y. Wong7
1Technische Universitat Munchen, Munich, Germany; 2Capital Medical Associates, Washington, DC, USA; 3Tarrant County Infectious Disease Associates, Fort Worth, TX, USA; 4University of Modena and Reggio Emilia, Modena, Italy; 5Janssen Research & Development, LLC, Titusville, NJ, USA;
6Janssen Research & Development, LLC, Pennington, NJ, USA; 7Janssen Scientific Affairs, LLC, Titusville, NJ, USA
![1003181](../images%20/100218/100318-5/1003181.gif)
![1003182](../images%20/100218/100318-5/1003182.gif)
![1003183](../images%20/100218/100318-5/1003183.gif)
![1003184](../images%20/100218/100318-5/1003184.gif)
![1003185](../images%20/100218/100318-5/1003185.gif)
![1003186](../images%20/100218/100318-5/1003186.gif)
![1003187](../images%20/100218/100318-5/1003187.gif)
![1003188](../images%20/100218/100318-5/1003188.gif)
![1003189](../images%20/100218/100318-5/1003189.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|